Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.

Leukemia research - 1 Apr 2005

Cairoli Roberto, Beghini Alessandro, Morello Enrico, Grillo Giovanni, Montillo Marco, Larizza Lidia, Morra Enrica

Abstract excerpt

Aim of this study is to investigate the capability of Imatinib to induce an anti-leukemic effect in Core Binding Factor (CBF)-leukemia patients presenting either with extracellular juxtamembrane or kinase KIT mutations. On the basis of a screening analysis for KIT mutations, two patients with a kinase mutation and one with extracellular juxtamembrane mutation, in first or subsequent leukemic relapse, received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrimidines
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Cells

Share to Core Binding Factors

Share to Imatinib Mesylate

Share to Leukemia

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 15725473
DOI: 10.1016/j.leukres.2004.10.005

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.PMID 15725473Read ↗

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.Semantic proximity Read ↗

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.Semantic proximity Read ↗

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.Semantic proximity Read ↗

The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.Semantic proximity Read ↗

[The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].Semantic proximity Read ↗

Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.Semantic proximity Read ↗

KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis.Semantic proximity Read ↗

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.